SS
ZVRA icon

SBI Securities’s Zevra Therapeutics ZVRA Stock Holding History

SBI Securities’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.59K Sell
111
-701
-86% -$7.79K ﹤0.01% 2639
2026
Q1 		$7.57K Buy
812
+810
+40,500% +$7.3K ﹤0.01% 1852
2025
Q4 		$18 Buy
2
+1
+100% +$9 ﹤0.01% 3796
2025
Q3 		$10 Buy
+1
New +$10 ﹤0.01% 4033

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SBI Securities's ZVRA Position: Q2 2026 in Review

SBI Securities reduced its Zevra Therapeutics (ZVRA) stake by 86% in Q2 2026, selling an estimated $7.79K and leaving 111 shares worth $1.59K. The position accounts for ﹤0.01% of the portfolio, ranked #2639.

SBI Securities first reported a position in ZVRA in Q3 2025 and has held it in 4 quarters since. The position peaked at $7.57K in Q1 2026. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • SBI Securities held 111 shares of Zevra Therapeutics worth $1.59K as of Q2 2026.
  • SBI Securities sold 701 Zevra Therapeutics shares in Q2 2026, an estimated $7.79K.
  • Zevra Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2639 holding.
  • SBI Securities first reported a position in Zevra Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • SBI Securities's Zevra Therapeutics position peaked at $7.57K in Q1 2026.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.